Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: Results from a retrospective family cohort study

Archives of Internal Medicine

Volumn 167, Issue 3, 2007, Pages 282-289

  Van Vlijmen, Elizabeth F W ^a   Brouwer, Jan Leendert P ^a   Veeger, Nic J G M ^a   Eskes, Tom K A B ^b   De Graeff, Pieter A ^a   Van Der Meer, Jan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S;

ADOLESCENT; ADULT; ANTITHROMBIN DEFICIENCY; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC DISORDER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; COHORT STUDIES; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; PEDIGREE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33846999324     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.3.282     Document Type: Article

References (30)

1. Jordan WM. Pulmonary embolism. Lancet. 1961;2:1146-1147.
2. Records Unit and Research Advisory Service, Royal College of General Practitioners. Oral contraceptives and thromboembolic disease. J R Coll Gen Pract. 1967;13:267-279.
3. Gerstman BB, Piper JM, Freiman JP, et al. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol. 1990;19:931-936.
4. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease: World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1582-1588.
5. Jick H, Jick S, Gurewich V, Wald Myers M, Vasilakis C. Risk of idiopathic venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589-1593.
6. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323:131-134.
7. Anderson FA Jr, Brownell Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991;151:933-938.
8. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232:155-160.
9. Middeldorp S, Meijers JCM, van den Ende AE, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a crossover study. Thromb Haemost. 2000;84:4-8.
10. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84:15-21.
11. Middeldorp S, Henkens CMA, Koopman MW, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med. 1998;128:15-20.
12. Martinelli I, Taioli E, Buccarelli P, Akhavan S, Manucci M. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol. 1999;19:700-703.
13. Aznar J, Vaya A, Estelles A, et al. Risk of venous thrombosis in carriers of the thrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica. 2000;85:1271-1276.
14. Legnani C, Palareti G, Guazzaloca G, et al. Venous thromboembolism in young women: role of thrombophilic mutations and oral contraceptive use. Eur Heart J. 2002;23:984-990.
15. Santamaria A, Mateo J, Oliver A, et al. Risk of thrombosis associated with oral contraceptives in women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G2210A mutation of the prothrombin gene. Haematologica. 2001;86:965-971.
16. Pabinger I, Schneider B; GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost. 1994;71:548-552.
17. Simioni P, Sanson B-J, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81:198-202.
18. Brouwer JLP, Veeger NJGM, Kluin-Nelemans HC, van der Meer J. Multicausal pathogenesis of venous thromboembolism: evidence from a study in families with hereditary deficiencies of protein C, protein S, or antithrombin. Ann Intern Med. 2006;145:807-815.
19. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol. 1996;143:1257-1265.
20. Brouwer JL, Veeger NJ, Schaaf W, Kluin-Nelemans HC, van der Meer J. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III: results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol. 2005;128:703-710.
21. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
22. Danneberg J, Abbes AP, Bruggeman BJ, Engel H, Gerrits J, Martens A. Reliable genotyping of the G-20210-A mutation of coagulation factor II (prothrombin). Clin Chem. 1998;44:349-351.
23. Exner T, Triplett DA, Taberner D, Machin SJ; SSC Subcommittee for the Standardization of Lupus Anticoagulants. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost. 1991;65:320-322.
24. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43-52.
25. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
26. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1998:247-252.
27. Libourel EJ, Bank I, Meinardi JR, et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers: the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica. 2002;87:1068-1073.
28. Vossen CY, Conard J, Fontcuberta J, et al; European Prospective Cohort on Thrombophilia (EPCOT). Risk of a first thrombotic event in carriers of a familial thrombophilic defect. J Thromb Haemost. 2005;3:459-464.
29. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Family history and risk of venous thromboembolism with contraception: family history is important tool. BMJ. 2001;323:752.
30. Heijboer H, Brandjes DPM, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512-1516.